Drug discovery is being transformed by artificial intelligence, structural biology, and computational chemistry at a pace beginning to show up in clinical pipeline statistics. AlphaFold2’s release provided accurate three-dimensional protein structure predictions for virtually every protein in the human proteome, unlocking target classes previously considered undruggable. Generative AI platforms from Isomorphic Labs, Insilico Medicine, Recursion, and Exscientia are proposing novel molecular structures optimized for target affinity, selectivity, and developability from computational first principles.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Target Identification and Validation
• Structural Biology and AlphaFold
• Generative AI in Molecular Design
• Computational Chemistry and ADMET Prediction
• Hit Identification and Screening
• Hit-to-Lead and Lead Optimization
Table of Contents
1. Executive Summary
2. Landscape Overview
3. Target Identification and Validation
4. Structural Biology and AlphaFold
5. Generative AI in Molecular Design
6. Computational Chemistry and ADMET Prediction
7. Hit Identification and Screening
8. Hit-to-Lead and Lead Optimization
9. Competitive Landscape
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Program and Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Pfizer
Johnson & Johnson
Roche
Novartis
Merck
AstraZeneca
Bristol-Myers Squibb
AbbVie
Eli Lilly
Sanofi
